Malaria Sschistosomiasis
Conditions
Interventions
Combination therapy PZQ plus DHP
PZQ alone
Sponsors
Muhumbili University of Health and Allied Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. School children aged 5-15 years, both male and females 2. Live primarily in a study village/area. 3. School children confirmed schistosomiasis positive by urine filtration test for urinary schistosomiasis and kato-katz for intestinal schistosomiasis 4. School children confirmed malaria positive or negative by microscopy 5.Parent/s has/have consented for child to recruited in this study 6. The child has assented to participate 7. No Known or documented sensitivity to any of the drugs under test
Exclusion criteria
Exclusion criteria: 1. Patients without diagnosis of Schistosomiasis (tested negative for schistosomiasis) 2.A recent PZQ treatment before entry to the study(2 months) 3. Presence of danger signs and symptoms of severe malaria according to WHO criteria 4. Prior treatment of malaria within 14 days of study enrollement 5. Patient receiving any medication known to affect cytochrome P450 within 14 days of the study enrollement 6. Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Schistosomiasis treatment outcome defined as presence or absence of eggs in urine or stool at 1 month and 2moths period netween the new intervention(PZq+DHP) and PZQ alone arms | — |
Secondary
| Measure | Time frame |
|---|---|
| DHP and PZQ interaction (drug level);Pharmacogenetics of PZQ ad DHP for the presence of single nucleotide polymorphisim (SNPs);day 7 piperaquine plasma concetration + malaria treatment outcome using DHP in the presence of PZQ;safety + tolerability of the new intervention (adverse events) | — |
Countries
Tanzania
Contacts
Public ContactJoyce Masalu
Director of Research Publicatiom-MUHAS
Outcome results
None listed